Glaxosmithkline Pauses Maternal Respiratory Syncytial Virus Vaccine Clinical Trials And To Provide Update Soon

Glaxosmithkline Pauses Maternal Respiratory Syncytial Virus Vaccine Clinical Trials And To Provide Update Soon

By, Admin 22 February 2022

Glaxosmithkline Plc Announced That It Has Voluntarily Paused Enrolment And Vaccination In The Grace Phase Iii Trial (Nct04605159), Evaluating Its Potential Respiratory Syncytial Virus (Rsv) Maternal Vaccine Candidate, As Well As Two Other Trials Investigating This Candidate In Pregnant Women (Nct04980391, Nct05229068).The Grace Study Was Launched In 2020 And Evaluates The Safety Of Gsk'S Candidate Vaccine (Gsk38888660A) For Pregnant Mothers And Infants And How It Affects Infants Born To Vaccinated Mothers. The Product Contains A Recombinant Subunit Pre-Fusion Rsv Antigen That Has Shown Positive Safety And Immunogenicity Results In A Phase I/Ii Trial Presented At The Id Week Congress In October 2020.This Decision Was Made Following A Recommendation From The Independent Data Monitoring Committee Based On An Observation From A Routine Safety Assessment. Monitoring Safety Signals Is An Integral Part Of The Clinical Development Process For Potential New Vaccines.This Decision Does Not Impact The Ongoing Aresvi 006 Phase Iii Trial (Nct04886596) For Rsv Older Adults (60 Years And Above). This Trial Remains On Track With An Anticipated Data Readout In The First Half Of 2022.In Its Statement, Gsk Noted That Monitoring Safety Signals Is Part Of The Committee'S Routine Task And Is Vital To The Development Process. The Company Added That The Pause Does Not In Any Way Impact The Ongoing Aresvi 006 Phase Iii Study For Older Adults Aged 60 Years And Up And That It Remains On Schedule To Deliver Its First Data Readout In The First Half Of 2022.Glaxosmithkline Will Provide A Further Update On The Respiratory Syncytial Virus (Rsv) Maternal Vaccine Candidate In Due Course.Respiratory Syncytial Virus Is An Important Indication For Glaxosmithkline, With Investment In The Space Contributing To A Recent 34 Per Cent Jump In Spending On Vaccine R&D, And 2022 Is Shaping Up To Be A Key Year For Its Attempt To Claim A Significant Slice Of A Market Targeted By Rival Companies Including Astrazeneca, Sanofi And Pfizer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!